Nanobiotix Shares Drop 4.86% at the Close of January 6

Nanobiotix shares closed the session on Tuesday, January 6, 2026, at 17.24 euros, down by 4.86% compared to the previous day. The biotech company, specialized in nanomedicine, now shows a decline of 10.58% over the last seven days, following an exceptional surge of 472.8% over the year. The traded volumes accounted for 0.6% of the capital, reflecting moderate activity in a context of profit-taking. The price is below its 50-day moving average (18.11 euros), indicating short-term selling pressure. The RSI stands at 31, nearing the oversold zone (threshold of 30), which could suggest a weakening of the downward movement. The stock is also trading below the identified support level of 17.06 euros, hinting at a possible search for new equilibriums before a technical rebound.

The decline occurs as the company enjoys a favorable consensus among analysts. Oddo BHF maintains an outperform rating with a target price raised to 28 euros in mid-December 2025, representing a potential upside of 62% from the current price. Leerink Partners also maintains a positive outlook with a target of 26 euros, confirming the appeal of the case for savvy investors. Strategically, in early November 2025, Nanobiotix secured a non-dilutive funding of 71 million dollars from HealthCare Royalty, extending its financial visibility until early 2028. These resources are intended to support the clinical development of its flagship product NBTXR3 in head, neck, and lung cancers. The management will participate from January 12 to 15 at the J.P. Morgan Healthcare Conference in San Francisco, a strategic meeting of the sector that could bring new announcements.